Abstract Sclerosing adenosis (SA) increases risk for invasive breast cancer (BC) 2.1 times relative to that in the general population. Here, we sought to evaluate whether the proliferation marker Ki-67 stratifies risk among women with SA. A nested case-control sample of patients with SA was obtained from the Mayo Clinic Benign Breast Disease Cohort. Ki-67 expression was evaluated in SA lesions and in the adjacent normal terminal duct lobular units (TDLU) in women who did (cases, n = 133) or did not (controls, n = 239) develop BC. Ki-67 was scored by intensity and number of positively stained cells per one high-power field (magnification, 940) (409 HPF) for both SA and normal TDLU. Associations of Ki-67 expression with case-control status were assessed using conditional logistic regression. Higher Ki-67 expression was significantly associated with case-control status in both SA (P = 0.03) and normal background TDLU (P = 0.006). For the SA lesion, [2 average positively stained cells/409 HPF showed an adjusted odds ratio (OR) of 1.9 (95 % CI, 1.1-3.4) compared to samples with an average of B2 positively stained cells. 
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Introduction
Sclerosing adenosis (SA) is a benign lobulocentric lesion of disordered acinar, myoepithelial, and connective tissue elements that can mimic infiltrating carcinoma both grossly and microscopically [1] . SA is a form of fibrocystic change with unknown etiology that is a combination of adenosis (epithelial and myoepithelial proliferation of lobules) and stromal sclerosis [2] . The incidence of SA has been found to decline after menopause, perhaps as an abnormal pattern of age-related regression or an abnormal involutional process after lactation [3] [4] [5] . SA is strongly associated with a complex of various lesions, including calcification, moderate to florid epithelial hyperplasia, apocrine change, intraductal papillomas, and atypical lobular hyperplasia [1] . It is found in association with atypical lobular hyperplasia almost 3 times as often as in otherwise benign breast specimens [1, 3] . SA commonly occurs in perimenopausal women and has a weak association with a family history of invasive breast carcinoma [1] . A diagnosis of SA is associated with a 1.5-2.1 times relative risk for development of breast cancer (BC), independent of its association with other proliferative lesions; thus, it is included with histologic lesions designated as proliferative disease without atypia [1, 6, 7] . In one study, the risk for patients with both SA and atypical hyperplasia was 6.7 compared to only 1.7 for patients with SA alone [1] .
The proliferation marker Ki-67 is expressed in normal breast tissue, atypical hyperplasia, and carcinoma [8] [9] [10] . Higher Ki-67 expression correlated with poorer clinical outcome in patients with invasive BC [10] and with increased risk of subsequent BC in women with atypia [9] .
We hypothesize that measures of proliferative index might identify women with increased risk of subsequent BC. Using a monoclonal antibody that recognizes Ki-67, the nuclear antigen present in proliferating cells, we evaluated the proliferation status of SA and neighboring normal terminal duct lobular units (TDLU) in women who developed BC (cases) compared with controls matched by year of biopsy and age [11] . Additionally, we assessed the association of Ki-67 expression in SA and adjacent normal TDLU with age, histologic impression, family history of BC, and lobular involution status.
Materials and methods

Study population
Patients with SA on a benign biopsy were randomly selected for this nested case-control study from an institutional cohort with benign breast disease (BBD) known as the Mayo BBD Cohort. Earlier reports have described cohort inclusion and exclusion criteria, characteristics, and available pathologic specimens [6, 12] . The Mayo Clinic Institutional Review Board approved this study.
The study population included 9076 women aged 18-85 years, who had surgical excision of a benign breast lesion at Mayo Clinic, Rochester, Minnesota, between January 1, 1967, and December 31, 1991. The histologic slides of these women were reviewed by an expert breast pathologist (DWV) for characterization of the different histologic lesions including SA, as part of the initial cohort development, and subsequently reviewed by another breast pathologist (AN) for confirmation of SA lesions in the study sections. BC events and family history (negative, weak, or strong) were obtained from medical records and questionnaires. A strong family history was defined as at least one first-degree relative with BC before age 50 years or as two or more relatives (one first-degree) with BC.
SA was defined as a tumor-like lobulocentric proliferation of epithelium and myoepithelium classified as a proliferative lesion (Fig. 1) . SA was included in the ''proliferative fibrocystic changes'' category if present in at least two foci, with at least one having a diameter greater than 1 normal lobule (Fig. 1) ; otherwise, it was considered nonproliferative. These criteria distinguished adenosis from lobular involution with sclerosis.
Study samples
This study was designed as a nested case-control study among the Mayo BBD cohort subset of women with pathologic findings of SA. Cases were women who developed BC during follow-up, whereas controls remained cancer-free longer than the time to cancer in matched cases. Cases and controls were additionally matched by age and year at biopsy. For inclusion, a sample required at least one SA lesion for scoring. The planned sample size was 300 controls matched 2:1-150 cases to provide 80 % power to detect odds ratios (ORs) of C2.0, assuming exposure frequencies as low as 20 % and a correlation of exposure between cases and controls of 0.2 for a 2-sided test with a = 0.05.
Immunohistochemistry staining
Immunohistochemistry staining was performed using the Leica Bond III Stainer (Leica Microsystems Inc, Buffalo Grove, Illinois). An ethylenediaminetetraacetic acid-based solution (Epitope Retrieval Solution 2; Leica Microsystems Inc) was used for Ki-67 for 20 min at 100°C. Samples were treated with 3 % H 2 O 2 for 5 min to inactivate endogenous peroxides. The primary antibody was incubated for 15 min at room temperature. Slides were incubated with a reference mouse monoclonal primary antibody against Ki-67 (Clone Mib-1; 1:300 dilution; Dako North America Inc, Carpinteria, California; Agilent Technologies Inc). The detection system was a 2-step polymer detection system (Bond Polymer Refine Detection; Leica Microsystems Inc), with each step incubated for 8 min.
Measurements
Ki-67 staining was scored using manual analysis based on (1) the number of positively stained cells per one highpower field (HPF) (magnification, 940) (409 HPF) and (2) intensity (no staining, weak, moderate, or strong). For each sample, up to three SA lesions and high-power field normal TDLUs were scored individually, as available. For samples with more than high-power field SA lesions or normal TDLUs, those with highest Ki-67 expression were scored. Intensity scores were assigned using numeric values: 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (strong staining). A product score was created by multiplying the number of positively stained cells/409 HPF by the intensity score.
Aperio image analysis (IA) quantitation was performed in a subsample for comparison to manual scores. Ki-67-stained sections from a random sample of 40 patients with proliferative SA were analyzed manually (using randomly selected lobules rather than ones with highest Ki-67 expression as described above) and digitally using digital microscopy hardware and software (Aperio Technologies Inc, Vista, California). In each section, B3 SA lesions and B3 normal TDLUs were selected (using an adjacent hematoxylin-eosin-stained section as a reference), and Ki-67 positive nuclei were measured manually and digitally. For manual counts, the number of positively stained cells per randomly chosen 40 9 HPF field was recorded. For digital counts, all slides were scanned at 209, producing highresolution images annotated using ImageScope analysis software (Aperio Technologies Inc). The number of positively stained cells in the entire lobule or lesion was calculated using a custom-designed nuclear ImageScope algorithm that identified nuclei and detected optical density of the chromogen of the Ki-67 immunostain. In each case, the number of positive cells was divided by the area to create a cell/area density; these values were multiplied by 1000 2 to convert from cells/micrometer 2 scale to cells/ mm 2 .
Statistical methods
For analysis, scores from the 1 to 3 measured lesions of each type (SA and normal TDLU) were summarized using the mean per lesion type. Analysis of the maximum value was performed but showed results similar to the average scores, so data are presented only for average scores. The association of Ki-67 staining with case-control status was assessed using conditional logistic regression to account for the matched case-control design. Restricted cubic splines with three knots placed at the 10th, 50th, and 90th percentiles were used to examine the functional form of the relationship between Ki-67 positively stained cells/ 409 HPF and case-control status [13] . Due to a strong right skew for both the number of signals and the product score, rank transformations were used in fitting statistical models. ORs were also estimated in quartile categories derived from the empirical distribution among controls. The association of Ki-67 staining with other variables, such as degree of lobular involution and age at BBD, was examined with generalized linear models to account for correlation within matched sets in estimating P values. The relationship between scores for SA lesion and normal TDLU within a sample was analyzed using the Wilcoxon signed-rank test and Spearman rank correlations. Samples with sufficient tissue for inclusion were compared to samples excluded for unavailable or insufficient tissue using the v 2 and 2-sample t tests. Agreement between manual and digital Ki-67 measures was assessed using the intraclass correlation coefficient (ICC) and the Wilcoxon signed-rank test to test for bias between the 2 measures. Descriptive statistics for continuous variables were generally reported using the median and interquartile range (IQR) except where otherwise noted. P \ 0.05 was considered statistically significant. Statistical analysis was performed using SAS (version 9.3; SAS Institute Inc, Cary, North Carolina) and R (version 3.0.2; http://www.r-project. org/), including the rms package [14] .
Results
Patients
The original matched case-control set included 150 cases and 300 controls. Upon review, not all samples were usable, most frequently because of insufficient sample (e.g., no SA lesion remaining in the block available for sectioning). If one control remained usable, a second replacement control was not identified. An attempt was made to replace case-control pairs that had either the case or both controls excluded. Seventeen originally matched cases and 61 originally matched controls were not usable and not replaceable. Thus, the sample size for final analysis included 133 cases matched to 239 controls (106 cases with 2 controls; 27 cases with 1 control). Excluded samples showed a significantly lower percentage with a palpable lump and both a higher degree of involution and older age (mean age, 59 years vs 52 years; P \ 0.001), differences suggesting that excluded samples had somewhat smaller SA lesions and more involuted lobules than included samples. Characteristics of the included samples are summarized in Table 1 (Fig. 2) . Generally, the number of positively stained cells/409 HPF showed more discrimination between cases and controls than did the intensity or product scores. The Ki-67 expression median score was 4.67 and 4.00 positively stained Table 2 ). However, examination of a restricted cubic spline fit (Fig. 3a) suggested a nonlinear functional form, with risk increasing initially but then flattening out and remaining stable. This relationship is also evident in 
Ki-67 expression in normal TDLU
At least one normal TDLU was available for scoring in 343 subjects (119 cases; 224 controls) (Fig. 4) . Generally, the normal TDLUs showed fewer positively stained cells/ 409 HPF than the SA lesions, but the difference was small (median paired difference, -0.5; IQR, -3 to 1; P \ 0.001). Comparing the SA lesion average to the normal TDLU average within sample, the SA lesion showed a higher Ki-67 count in 57 %, while the normal was higher in 36 %, and they were the same in 7 %. Ki-67 expression in normal TDLUs showed moderate correlation with expression in SA lesions (r = 0.59). Median Ki-67 expression was 3.67 and 3.00 positively stained cells/409 HPF for cases and controls, respectively (P = 0.006) ( Table 2 ). The number of Ki-67 signals in normal TDLUs remained significant (P = 0.03) after adjustment for standard variables associated with BC risk (age, histologic impression, degree of lobular involution, and family history of BC). As with Ki-67 in the SA lesion from each sample, Ki-67 in normal TDLU from each sample demonstrated nonlinear functional form, with odds of BC increasing but then leveling off across higher values (Fig. 3b) . ORs by quartile (Table 3) showed an unadjusted OR of 1. 
Discussion
This study is the first to address Ki-67 as a biomarker specific to SA, a benign proliferative lesion associated with an approximate doubling of risk for BC relative to the general population [7] . This study characterized Ki-67 expression as the number of positively stained cells/ 409 HPF, due to the relatively low frequency of these cells in benign breast tissues compared to cancers. IQR interquartile range, TDLU terminal duct lobular unit, 409 HPF high-power field (magnification, 940) a P values were calculated from the conditional logistic regression model. The number of signals and product score variables was rank transformed prior to this analysis b P values were adjusted for the presence of atypia, degree of lobular involution, indication for biopsy (lump or mammogram), and family history of breast cancer (none, weak, or strong)
In this nested case-control study of BBD patients with C1 SA lesions, higher Ki-67 expression in either the SA lesion or the adjacent normal TDLU was associated with increased odds of BC during follow-up. The increased risk did not appear to increase linearly with increasing numbers of Ki-67 positively stained cells but rather increased to a threshold level and stayed relatively stable. For SA lesions, the expression of Ki-67 at a rate of [2 average positively stained cells/409 HPF was associated with an increased risk for future development of BC. Whereas for normal TDLUs, the expression of Ki-67 at a rate of [6 average positively stained cells/409 HPF increases a woman's risk for developing BC. The findings with respect to normal TDLUs are particularly compelling in that histologically normal lobules from the biopsy slide show differential Ki-67 associated with future BC risk.
These results are generally consistent with the literature on Ki-67 as it relates to BC in finding that higher Ki-67 Fig. 3 Functional form of relationship between Ki-67 expression in a sclerosing adenosis (SA) lesion (a) and in a normal terminal duct lobular unit (TDLU) (b) with estimated log (odds) of breast cancer. Estimated log (odds) values were derived from conditional logistic regression using restricted cubic splines, with knots at the 10th, 50th, and 90th percentiles. For improved visualization of the form, a smoothing curve was overlaid using a locally estimated scatterplot smoother (loess). HPF indicates high-power field Our group has previously studied Ki-67 immunoreactivity in Mayo BBD subjects with atypical hyperplasia (N = 192 women), using a cutoff of 2 % positive cells to separate the group into high and low expressers (9) . Women with high expression (C2 %) in the atypia lesion had a shorter time to BC development in the first 10 years of follow-up [9] . Whereas women with low Ki-67 expression (\2 %) showed increased risk of BC after 10 years of follow-up [9] . In the current study, we found no significant association between Ki-67 expression and time to cancer in cases.
Previous studies have found that Ki-67 expression shows a progressive increase across the continuum from BBD, to atypical ductal hyperplasia, to ductal carcinoma in situ (DCIS), and invasive carcinoma [8, 15] . Its high expression ([11 %) has been correlated with worse prognosis in invasive BC [10] . In a study comparing BC with adjacent nonmalignant tissue, higher Ki-67 cell expression was noted in breast carcinoma cells (25 %) and lower Ki-67 expression was noted in fibrocystic changes with atypia and fibroadenoma (3-4 %) [16] . In another study examining BC, DCIS, and adjacent nonmalignant tissue, the mean value of Ki-67 proliferation in cases with DCIS showed a threshold increase of up to 16.8 %; with invasive carcinoma, it was 23.3 % [17] . Similarly, in a comparison of benign and malignant BC tissue, the mean Ki-67 proliferating index was 4.4 and 16.1 % for benign and malignant breast groups, respectively (P \ 0.001) [18] .
Strengths of our study include a well-characterized BBD cohort with long-term follow-up, plus review by a breast pathologist to capture Ki-67 immunoreactivity in both SA and normal TDLU. A limitation was that not all of the selected case-control pairs could be analyzed due to insufficient tissue, possibly introducing a slight bias in this retrospective case-control study.
In conclusion, patients with SA showed variable Ki-67 expression in both the SA lesion and the adjacent normal TDLU. Ki-67 expression was associated with other BC risk features and future BC case status. Specifically, higher Ki-67 expression in either the SA lesion or the normal TDLU had an OR approximately twofold compared to lower Ki-67 expression. Furthermore, manual and digital scoring using Aperio IA quantitation showed excellent agreement.
